While these drugs are still in the early phase of their clinical development, the initial use of the Chk1 antagonist prexasertib in ovarian cancer patients has been associated with good tolerability with the only grade 3-4 adverse events related to decreased white blood cell counts and neutropenia (61). Here, CHEK1 is linked to ovarian carcinoma.